Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Spermosens

0.01 SEK

0.00 %

Less than 1K followers

SPERM

Spotlight Stock Market

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
0.00 %
+6.67 %
-5.88 %
-8.57 %
-52.24 %
-50.77 %
-97.03 %
-
-99.34 %

Spermosens are active in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical data and potential fertilization. The largest operations are in the Nordic market.

Read more
Market cap
20.31M SEK
Turnover
10.69K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11.2.
2026

Annual report '25

All
Press releases
ShowingAll content types
Regulatory press release4 hours ago

Spermosens announces outcome of exercise of warrants series TO 4

Spermosens
Regulatory press release11/24/2025, 4:12 PM

Spermosens announces last day of trading for warrants of series TO 4

Spermosens
Regulatory press release11/18/2025, 9:21 AM

Spermosens receives patent approval in China

Spermosens

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release11/12/2025, 8:04 AM

Spermosens AB (publ) INTERIM REPORT JANUARY - SEPTEMBER 2025

Spermosens
Regulatory press release11/4/2025, 4:21 PM

Spermosens receives patent approval in Israel

Spermosens
Regulatory press release11/3/2025, 11:31 AM

Spermosens receives patent approval in Mexico

Spermosens
Regulatory press release10/22/2025, 9:17 AM

Spermosens receives patent approval in Canada

Spermosens
Regulatory press release8/20/2025, 7:38 AM

Spermosens AB (publ) INTERIM REPORT JANUARY - JUNE 2025

Spermosens
Press release8/7/2025, 6:30 AM

Spermosens provides status update following successful clinical study

Spermosens
Regulatory press release6/17/2025, 12:16 PM

Spermosens announces outcome of exercise of warrants series TO 5

Spermosens
Regulatory press release6/16/2025, 9:15 AM

Spermosens AB Announces Results from Annual General Meeting on 16 June 2025

Spermosens
Regulatory press release6/13/2025, 11:04 AM

Chairman and CEO of Spermosens exercise TO5 warrants

Spermosens
Regulatory press release6/11/2025, 10:48 AM

Spermosens concludes clinical study with statistically significant results supporting the diagnostic value of JUNO-Checked

Spermosens
Regulatory press release6/5/2025, 7:09 PM

Spermosens: The capital raise and issue announced in March 2025 is approved by Inspectorate of Strategic Products

Spermosens
Regulatory press release6/5/2025, 10:27 AM

Last day of trading in warrants series TO 5 in Spermosens is 12 June 2025

Spermosens
Regulatory press release6/2/2025, 6:45 AM

Spermosens: The subscription price for warrants of series TO 5 has been determined - the exercise period begins today

Spermosens
Regulatory press release5/26/2025, 10:06 AM

Spermosens publishes annual report for the financial year 2024

Spermosens
Regulatory press release5/15/2025, 6:51 AM

Spermosens: NOTICE OF ANNUAL GENERAL MEETING 2025 IN SPERMOSENS AB (publ)

Spermosens
Regulatory press release5/7/2025, 7:10 AM

Spermosens AB (publ)INTERIM REPORT JANUARY - MARCH 2025

Spermosens
Press release4/30/2025, 10:48 AM

Spermosens provides update on clinical progress, partner discussions and financing

Spermosens
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.